Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Phase 4

Conditions: HIV

Interventions: Drug: darunavir ritonavir raltegravir
Drug: atripla

First Posted Date: 2011-04-28

Last Posted Date: 2011-04-28

Lead Sponsor: East Carolina University

Target Recruit Count: 40

Registration Number: NCT01343225

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Cenicriviroc 100 mg
Drug: Cenicriviroc 200 mg + Truvada
Drug: Sustiva + Truvada

First Posted Date: 2011-04-20

Last Posted Date: 2013-07-10

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 143

Registration Number: NCT01338883

Locations: 🇺🇸
Oasis Clinic, Los Angeles, California, United States
🇺🇸
Anthony Mills, Los Angeles, California, United States
🇺🇸
Providence Clinical Research, Burbank, California, United States

and more 45 locations

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Not Applicable

Terminated

Conditions: HIV

Interventions: Drug: Raltegravir
Drug: Efavirenz

First Posted Date: 2011-02-10

Last Posted Date: 2019-10-31

Lead Sponsor: University of California, San Diego

Target Recruit Count: 2

Registration Number: NCT01293123

Locations: 🇺🇸
UCSD Antiviral Research Center, San Diego, California, United States

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2011-01-07

Last Posted Date: 2013-05-13

Lead Sponsor: Kirby Institute

Target Recruit Count: 40

Registration Number: NCT01271894

Locations: 🇿🇦
Desmond Tutu HIV Foundation, Cape Town, South Africa
🇬🇧
Chelsea and Westminister Hospital, London, United Kingdom
🇹🇭
Thai Red Cross-AIDS Research Centre, HIV-NAT Research Collaboration, Bangkok, Thailand

and more 1 locations